Clinical Trial Update: An Extension of Protocol PRO 140_CD01 Study [Phase 2]

View source ↗

Summary

A Phase 2 extension of the PRO 140_CD01 HIV study was terminated; results have been posted for the extension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Leronlimab (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV, Human Immunodeficiency Virus | Phase 2 | Status: TERMINATED | Results posted: 2025-10-07